Humacyte, Inc. (NASDAQ:HUMA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Humacyte has a “Moderate Buy” consensus rating from seven analysts, with six buys and one sell. The average 12-month price target is $6.54.
• HUMA shares opened at $0.60, near their 52-week low of $0.53 and well below the 52-week high of $2.55. The company recently reported a quarterly loss of $0.16 per share and revenue of $0.41 million, both worse than analyst expectations.
• Institutional investors and hedge funds own 44.71% of Humacyte, with several firms initiating positions during the second quarter. The clinical-stage biotechnology company is developing regenerative human acellular vessels for vascular access and repair applications.

Humacyte, Inc. (NASDAQ:HUMA - Get Free Report) has been assigned an average rating of "Moderate Buy" from the seven research firms that are presently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and six have issued a buy rating on the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is $6.5417.

HUMA has been the topic of a number of analyst reports. Wall Street Zen lowered Humacyte from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 15th. HC Wainwright raised their price objective on Humacyte from $3.00 to $4.00 and gave the stock a "buy" rating in a research report on Thursday, June 11th. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of Humacyte in a research note on Wednesday, July 8th. TD Cowen reduced their target price on Humacyte from $1.50 to $1.25 and set a "buy" rating on the stock in a report on Wednesday, June 17th. Finally, Benchmark decreased their target price on shares of Humacyte from $2.00 to $1.00 and set a "speculative buy" rating for the company in a research report on Thursday, August 13th.

Humacyte Price Performance

Shares of NASDAQ:HUMA opened at $0.60 on Friday. The firm has a market cap of $168.04 million, a PE ratio of -1.23 and a beta of 2.45. The firm's fifty day moving average is $0.67 and its 200-day moving average is $0.86. The company has a debt-to-equity ratio of 2.07, a quick ratio of 5.74 and a current ratio of 6.21. Humacyte has a 52 week low of $0.53 and a 52 week high of $2.55.

Humacyte (NASDAQ:HUMA - Get Free Report) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.05). The company had revenue of $0.41 million during the quarter, compared to analyst estimates of $1.04 million. Humacyte had a negative net margin of 4,556.29% and a negative return on equity of 983.32%. Sell-side analysts predict that Humacyte will post -0.4 earnings per share for the current year.

Institutional Investors Weigh In On Humacyte

Several large investors have recently modified their holdings of the company. Alyeska Investment Group L.P. bought a new position in Humacyte during the second quarter worth $4,700,000. Beacon Pointe Advisors LLC bought a new stake in Humacyte during the second quarter valued at $28,000. Stonepine Capital Management LLC acquired a new stake in Humacyte during the 2nd quarter worth about $180,506. Bank of America Corp DE acquired a new stake in Humacyte during the 2nd quarter worth about $451,000. Finally, Ieq Capital LLC bought a new position in shares of Humacyte in the 2nd quarter worth about $218,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company's proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient's own tissue. Humacyte's primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company's lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.